A study recently published in the New England Journal of Medicine suggests that the biologic, dupilumab, was effective in treating uncontrolled moderate to severe asthma.
Dupilumab is a biologic, or antibody therapy that acts to block a specific mechanism to decrease allergic inflammation. In this study of 1902 patients, patients on the medication had a decrease rate of asthma exacerbation as well as improvement in their breathing test scores.
Currently, dupilumab is only FDA approved for moderate to severe eczema which is another allergic condition. The FDA is in the process of reviewing dupilumab for use for asthma. For more information on the article, click the link: www.nejm.org/doi/full/10.1056/NEJMoa1804092